65,437 trials
Cerebral Palsy · Sensorimotor Deficits · Sensory Processing Disorder
Primary: A Priori H1. The Number of Days to Achieve Oral Feeding Between the Intervention Group and the Matched Historical Comparison Group - From All Tube to All Oral Feeding…
Bowel Preparation
Primary: Percentage of Participants Classified as Successes (Excellent and Good Ratings) According to the Aronchick Scale As Assessed by a Blinded Gastroenterologist — 83.0; 79.7…
Restless Legs Syndrome
Primary: Number of Reported Adverse Events — 8; 1; 2; 1 cases
Liver Dysfunction
Primary: Changes in the M30 and M65 Markers Related to the Anesthesia Type — 237.27; 279.97; 427.33; 470.30 U/L
B-Cell Lymphoma
Primary: Clinical Response Rate — 1; 7; 0; 8 Participants
Heart Failure
Primary: Diuretic Efficacy Index 1 for Sodium Excretion — 10.185; 12.122; 13.453; 12.858 mmol/mg
Depression · Panic Disorder
Primary: Number of Treatment Related Adverse Events (TRAEs) Not Expected From Japanese Package Insert — 2; 1; 1 events
Schizophrenia
Primary: Incidence of Adverse Events — 97.4 percentage of patients
Glioblastoma · Gliosarcoma
Primary: Response Rate — 24.4 percentage of patients
Third Degree Burn · Burns · Wound Infection
Primary: Percent Autograft Take on Wounds Prepared by StrataGraft™ Skin Tissue. — 97.7; 96.7 Percent Area of Autograft Take (%)
Burns
Primary: Percentage of Grafted Area That is Viable at Day 14 — 96.3; 96.0 Percentage area
Attention Deficit Hyperactivity Disorder · Nicotine Dependence
Primary: The Number of Subjects in Each Treatment Group Exhibiting Sustained, 4-week Smoking Abstinence, Defined as CO Levels <= 4 Ppm for Each Post-quit Study Visit. — 5; 3…
Type 2 Diabetes Mellitus
Primary: Number of Participants Experiencing Adverse Events (AEs) On Study — 2; 3; 3; 2 participants
Perennial Allergic Rhinitis
Primary: Percentage of Subjects With Clinically Relevant Change From Baseline (Day 0) in Nasal Examination Parameters to Exit (Month 12 or Sooner) — 0.8; 1.3; 0.3; 0.8 Percentage…
Adult T-Cell Leukemia and Lymphoma (ATL) · Adult Peripheral T-Cell Lymphoma (PTCL)
Primary: Incidence of Dose-Limiting Toxicities (DLTs) — 1 participants